TITLE

Developing the evidence for evidence-based practice

AUTHOR(S)
Rush, A. John
PUB. DATE
May 2008
SOURCE
CMAJ: Canadian Medical Association Journal;5/6/2008, Vol. 178 Issue 10, p1313
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The article relates the author's perspective on a study which examines the efficacy and acceptability of long-term therapy with selective serotonin reuptake inhibitors in the treatment of depression, published within the issue. He asserts that the systemic review conducted by the authors of the study suggests that patients with depression who have medical comorbidities may not benefit from treatment over the longer term. He remarks that relevant evidence to inform decision-making is needed.
ACCESSION #
31772323

 

Related Articles

  • Relighting the Inner Flame. Klotter, Jule // Townsend Letter;Jan2007, Issue 282, p72 

    The article discusses the significance of selective serotonin reuptake inhibitors (SSRI) in treating mental depression in the U.S. The author discusses the withdrawal effects of the drug and argues that the drugs are necessary for the patient's health. Moreover, she emphasizes the importance of...

  • Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. Deshauer, Dorian; Moher, David; Fergusson, Dean; Moher, Ester; Sampson, Margaret; Grimshaw, Jeremy // CMAJ: Canadian Medical Association Journal;5/6/2008, Vol. 178 Issue 10, p1293 

    Background: Selective serotonin reuptake inhibitors are increasingly used in the long-term treatment of depression. Much of the supporting evidence about the effects of these drugs comes from discontinuation trials, a variant of randomized controlled trials whose design is problematic to...

  • No formulary should restrict itself to one SSRI for the treatment of depression. Zablocki, Elaine // Managed Healthcare Executive;Feb2004, Vol. 14 Issue 2, p40 

    Examines the efficacy of selective serotonic reuptake inhibitors for the treatment of depression. Capability of serotonin to enhance patient's mood; Ability to increase the level of neurotransmiter serotonin; Side-effects of serotonin.

  • FDA APPROVES DESVENLAFAXINE SUCCINATE FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER. J. C. // Primary Psychiatry;May2008, Vol. 15 Issue 5, p25 

    The article reports on the approval of desvenlafaxine succinate, a serotonin norepinephrine reuptake inhibitor, by the U.S. Food and Drug Administration to treat adult patients with major depressive disorder (MDD). Accordingly, its efficacy was established through four, 8-week randomized,...

  • Los antidepresivos inhibidores selectivos de recaptura de serotonina (ISRS, ISR-5HT). Chávez- León, Enrique; Patricia Ontiveros Uribe, Martha; Serrano Gómez, Carlos // Salud Mental;jul/ago2008, Vol. 31 Issue 4, p307 

    Depression is a frequent mental disorder in the general population. Approximately 3.7% of the population will suffer a major depressive episode throughout life. Pharmacological treatment with selective serotonin receptor inhibitors (SSRIs) is useful to treat this condition and other mental...

  • Investigating Outcomes Following the Use of Selective Serotonin Reuptake Inhibitors for Treating Depression in Pregnancy. Grzeskowiak, Luke E.; Gilbert, Andrew L.; Morrison, Janna L. // Drug Safety;2011, Vol. 34 Issue 11, p1027 

    The aim of this review was to critically appraise the existing literature with a particular focus on identifying methodological issues associated with studying outcomes following the use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy. Existing studies evaluating outcomes...

  • Review: selective serotonin reuptake inhibitors as effective as tricyclic antidepressants for major depression, and may have fewer adverse effects. Cipriani Andrea // Evidence Based Mental Health;Nov2003, Vol. 6 Issue 4, p117 

    Assesses the effectiveness and safety of selective serotonin reuptake inhibitors compared with tricyclic antidepressant in people with depression treated in primary care. Results showing that severity of depression varied among participants and that selective serotonin reuptake inhibitors and...

  • Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine. De Jong, Trynke R.; Pattij, Tommy; Veening, Jan G.; Waldinger, Marcel D.; Cools, Alexander R.; Olivier, Berend // Psychopharmacology;May2005, Vol. 179 Issue 2, p509 

    Discusses a research on the difference between fluvoxamine and paroxetine in relation to the effects of chronic selective serotonin reuptake inhibitors (SSRIs) on 8-hydroxy-2-(di-n-propyl-amino)tetralin-induced facilitation of ejaculation in rats. SSRIs that treat depression; Components of...

  • Depression: epidemic or pseudo-epidemic? Summerfield, Derek // Journal of the Royal Society of Medicine;Mar2006, Vol. 99 Issue 3, p161 

    The article examines the medical literature of the term depression. It infers that the history of the concept demonstrates the incorporation of a Western cultural vocabulary of fatigue and stress. It offers information on the Defeat Depression campaign implemented by the Royal Colleges of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics